You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 8, 2025

Claims for Patent: 8,129,405

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,129,405

Title:	Quinuclidine derivatives and medicinal compositions containing the same
Abstract:	The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2]octane bromide in powder inhalant form, and methods of using it for treatment of respiratory disorders.
Inventor(s):	Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee:	Almirall Prodesfarma S.A. (Barcelona, ES)
Application Number:	13/011,131
Patent Claims:	1. A pharmaceutical composition comprising: (i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo- [2.2.2] octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X.sup.- with a single negative charge is associated with the positive charge of the nitrogen atom; and (ii) a .beta..sub.2 agonist. 2. The composition of claim 1 further comprising a pharmaceutically acceptable carrier or diluent. 3. The composition of claim 1 wherein the anion X.sup.31 is chloride, bromide, iodide, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p-toluenesulfonate, or trifluoroacetate. 4. The composition of claim 1 which is suitable for inhalation. 5. The composition of claim 1 wherein the composition is a liquid inhalant, powder inhalant, or inhalation aerosol. 6. The composition of claim 1 further comprising a steroid. 7. The composition of claim 6 further comprising a phosphodiesterase IV inhibitor. 8. The composition of claim 1 further comprising a phosphodiesterase IV inhibitor. 9. The composition of claim 2 wherein the pharmaceutically acceptable carrier or diluent is lactose. 10. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of the composition of claim 1. 11. The method of claim 10 further comprising administering an effective amount of a steroid. 12. The method of claim 11 further comprising administering an effective amount of phosphodiesterase IV inhibitor. 13. The method of claim 10 further comprising administering an effective amount of phosphodiesterase IV inhibitor.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.